Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study

Abstract

Background: In China, evidence regarding to the association between platelet to lymphocyte ratio (PLR) and glucocorticoid (GC) resistance in participants with primary newly identified immune thrombocytopenia (ITP) is limited. We aimed to investigate whether PLR is independently linked with GC-resistant ITP. Material/Methods: We non-selectively and consecutively collected 154 newly diagnosed ITPs. The start enrollment time and the end enrollment time were from March 2013 to June 2017. The independent and dependent variables were PLR measured at diagnosis and GC non-response. Other variables involved in the present work can be summarized as demographic data and factors that were correlated with PLR reported by published studies. Univariate and multivariate binary logistic regression model and sensitivity analysis were used to evaluate the associations between PLR and GC resistance. Results: After adjusting covariates, PLR level was negatively associated with GC non-response [odds ratio (OR)=0.89, 95% confidence intervals (CI): 0.80 to 0.98], and supported by propensity score matching model (OR=0.74, 95%CI: 0.57 to 0.96]. Nonlinearity of PLR and GC resistance was observed whose inflection point was 5.08 (by 2-piecewise model). The OR and 95%CI on both sides of inflection point were 3.14 (0.81 to 12.21) and 0.81 (0.69 to 0.95), respectively. Subgroup analysis showed no significant differences from subgroups. Conclusions: Threshold effect on PLR and GC resistance is observed. When PLR is larger than 5.08, a unit increase of PLR is independently associated with 19% reduction of GC resistance.

Recombinant human thrombopoietin therapy for primary immune thrombocytopenia in pregnancy: a retrospective comparative cohort study

“…In our study, pregnant patients with ITP who failed first-line therapy with higher baseline PLR levels were more responsive to rhTPO. This result is consistent with that of a previous study [14]. In addition to its direct role in stimulating platelet production by megakaryocytes, rhTPO has demonstrated additional effects on immune regulation [10,11].…”

“…Moreover, the clinical predictors associated with the therapeutic effects of rhTPO remain unclear. Studies have demonstrated a correlation of mean platelet volume (MPV) [12,13] and platelet-to-lymphocyte ratio (PLR) [14,15] with the efficacy of treatment in ITP patients. However, to our knowledge, no studies have investigated the relationship between these predictors and the therapeutic efficacy of rhTPO in pregnant patients with ITP.…”